FNDC11

Across TCGA pan-cancer cohorts, FNDC11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FNDC11 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FNDC11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FNDC11 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

GBM, HNSC, and LUAD are the cancer types where FNDC11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.776	0.923	.025	4	view →
HNSC	DFS	Median	All	0.792	0.473	.035	3	view →
LUAD	OS	Quartile	All	1.000	0.909	.034	2	view →
LSCC	OS	Median	II,III,IV	0.586	0.915	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FNDC11–GBM (OS)

Open the GBM breakdown →